A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Jul 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Basalt-3
- Sponsors Novartis; Novartis Pharma A.G.
- 16 Mar 2017 This trial has been completed in UK (End date:2015-08-04) as per European Clinical Trials Database record.
- 16 Nov 2016 Status changed from completed to discontinued as review of safety and preliminary efficacy data showed marginal anti-tumor activity.
- 07 Jun 2016 Results from this trial and other trial (BASALT-2) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology